The efficacy and safety of probiotics intervention in attenuating cardiac remodeling following myocardial infraction: Literature review and study protocol for a randomized, double-blinded, placebo controlled trial

Jalal Moludi\textsuperscript{a,b}, Mohammad Alizadeh\textsuperscript{a,*}, Mina Davari\textsuperscript{a}, Ali Golmohammadi\textsuperscript{c}, Vahid Maleki\textsuperscript{a}

\textsuperscript{a} Nutrition Research Center, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran
\textsuperscript{b} Students’ Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
\textsuperscript{c} Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

\section*{A R T I C L E   I N F O}

Keywords:
Cardiac remodeling
Heart failure
Microbiome
Myocardial infraction
Probiotics

\section*{A B S T R A C T}

\textbf{Introduction:} Structural and functional changes that occur post myocardial infraction (MI) lead to the syndrome of heart failure (HF). However, their pathogenesis is poorly understood. Recently, alteration of the intestinal microbiota (dysbiosis) has emerged as a new candidate that may be correlated with risk of HF development. We hypothesized that selective gut modulation by probiotic administration may improve metabolic dysfunction and attenuate cardiac remodeling (CR) in MI subjects.

\textbf{Methods:} /Design: This article is presented in two sections: First, we provided a review of recent findings related to gut microbiota and CR and their association with probiotic supplementation. Secondly, we will conduct a randomized double-blinded controlled clinical trial in 46 Iranian patients with MI after successful percutaneous coronary intervention (PCI). The participants (age: \geq 30 years; ejection fraction (EF) greater than 30) will be selected by a simple random sampling method and will be assigned to 3 months of 1.6*10^9 CFU probiotic (Lactobacillus rhamnosus), or placebo groups (maltodextrin). The primary outcome is development of CR. The secondary outcomes measures include gut microbiota profile, biochemical variables and the safety of the probiotics supplementation. Also, echocardiography will be measured at baseline and following treatment. The data will be compared within and between groups using appropriate statistical methods.

\textbf{Discussion:} The results of this trial will provide evidence about the efficacy and safety of gut microbiota manipulation by probiotics in post-MI cardiac remodeling prevention.

\textbf{Ethical issues:} Present study protocol was approved by the regional committee of ethics in international branch of Tabriz University of Medical sciences (TBZMED) as a thesis proposal for PhD degree in Nutrition Sciences (IR.TBZMED.REC.1397.184).

\textbf{Trial registration} The Clinical trial was registered in the Iranian Registry of Clinical Trials (IRCT20121028011288N15).

\section*{1. Introduction}

Heart failure (HF) is important public health problems in that its prevalence and incidence has been growing dramatically since past decades. In recent years [1,2], despite considerable pharmacotherapy, such as angiotensin-converting enzyme [3], the five-year survival rate is still unacceptably poor [4,5]. Although different diseases, such as hypertension and diabetes, might lead to heart failure [6], adverse cardiac remodeling (CR) [4] after myocardial infarction (MI), can predispose a person to HF development [7]. In addition, quality of life has not been appropriately improved by current therapeutic modalities [8,9]. So, preventing this process and alternative treatments may be useful. In the present study, we aimed to review the current literature on the modulatory effects of gut microbiota in HF. Subsequently, we will specifically focus on probiotic supplementation to investigate the CR and metabolic endotoxemia amelioration. In current study, we will debate recent findings that reveal mechanisms connecting the gut microbiota to low-grade inflammation in context of cardiovascular disease (CVD). Additionally, we will discuss the potential relationships between the gut microbiota with CR. Lastly, we talk over the potential gut modulation and their effects on CR process.
2. Cardiac remodeling

A process of regional and global structural and functional changes in the heart result from cardiac load or injury [10,11]. The process of cardiac remodeling is influenced by degree of cardiac damage, inflammatory process, neurohormonal activation and other factors which are still under investigation [12,13]. Moreover, there is general acceptance that CR might cause HF [7]. CR is assessed by echocardiography, and elevated circulating biomarkers, such as B-type natriuretic peptide (BNP) or matrix metalloproteinase (MMP) 9 and several new biomarkers which has been introduced in recent years [14,15]. As well as, progressive left ventricular (LV) dilatation post-MI assessed by diastolic and systolic dimensions (LVDD and LVDS, respectively) and ejection fraction through electrocardiography can be regarded as CR detection methods [16].

It has long been accepted that HF is associated with altered intestinal function. As well as, metabolic endoxemia as a result of altered gut microbiota could influence HF [17]. More recently, preliminary animal CR model studies also demonstrated a direct mechanistic link between gut microbiota metabolites, and adverse ventricular dysfunction [17]. Indeed, it has been suggested that altered gut microbiota is prevalent in patients with HF [18]. However, the possible influence of gut modulation on HF pathogenesis is mostly unknown. At present, to the best of our knowledge, the association between gut metabolite and progress of HF has not been investigated. Given the proposed involvement of intestinal dysfunction and microbiota alterations in HF, we planned to investigate the association between gut microbiota, etiology and prognosis of CR process in MI patents.

3. Gut microbiota

The human gut microbiota has been identified as a possible novel risk factor [18]. Abnormal gut microbiota profiles (dysbiosis) have been associated with obesity, diabetes and CVD [19]. Exactly, in “metabolic endoxemia” condition, lipopolysaccharides (LPSs) of gram-negative cell wall are able to induce systemic low-grade inflammation, insulin resistance, and increase cardiovascular risk [20]. The binding of LPS with Toll-like receptor (TLR) 4, exert innate immune system stimulation leading to proinflammatory response and subsequent metabolic disorders. Besides its role in inflammation [21,22], TLR4 induces production of MMP 9, which has been proposed to be a marker for CR process [23]. Therefore, it is thought that TLR4 plays an important role in post MI remodeling, however, so far, the effect of gut modulation on TLR4 and subsequent on CR processes has not been investigated. Probiotics administration may be able to improve the inflammation, lipid profile and MI which are the main risk factor for CVD, also, maybe offsetting cardiac remodeling process (Fig. 1).

To the best of our knowledge, there is no clinical trial which explored whether probiotics administration can reduce cardiac remodeling process in patients with MI. Therefore, the primary objective of this study is to investigate the efficacy and safety of probiotics administration in preventing the development of post-MI remodeling in patent with successful percutaneous coronary intervention (PCI) via a parallel-group randomized double-blind placebo-controlled clinical trial. Left ventricular contractility and cardiac remodeling will be assessed by two-dimensional echocardiography and biomarkers will also be used to assess the remodeling.

5. The aims and hypotheses

5.1. General aim

The general aim of the current investigation is to determine the effects of three-month probiotic supplementation on preventing the development of post-MI remodeling and gut microbiota composition through a double-blind, randomized, placebo-controlled clinical trial in adults with successful percutaneous coronary intervention (PCI).
6. The specific aims and hypotheses

6.1. Aim 1

To determine whether probiotic supplementation improves ventricular contractility in individuals with successful PCI. We hypothesize that Lactobacillus rhamnosus supplementation will attenuate cardiac remodeling in these individuals compared with placebo. Cardiac remodeling will be assessed by two-dimensional echocardiography (including left ventricular end diastolic diameter (LVEDD), right ventricular end diastolic diameter (RVEDD), left ventricular end-diastolic volume (LVEDV), right ventricular end-diastolic volume (RVEDV) and Ejection Fraction [4] and biomarkers (including TGF. Beta, NT pro BNP, MMP-9, Procolagen I).

6.2. Aim 2

To determine whether probiotic supplementation will improve inflammatory stress indices, oxidative stress indices and lipid profiles in individuals with MI. We hypothesize that probiotic supplementation will reduce the serum level of high sensitivity C-reactive protein (hs-CRP), Interleukin 1 beta (IL1B), total cholesterol [6], triglyceride (TG), low-density lipoprotein (LDL), (ox-LDL) and malondialdehyde (MDA) and improve high-density lipoprotein (HDIL), total antioxidant capacity (TAC), and Interleukin 10 (IL-10) levels in these individuals.

6.3. Aim 3

To determine whether probiotic supplementation will improve metabolic endotoxemia and gut metabolite in individuals with MI. We hypothesize that probiotic supplementation will improve gut metabolites (TMAO) level and serum levels of endotoxemia (TLR4 and LPS) in these individuals.

6.4. Aim 4

To determine the changes in abundance and ratio of gut microbiota and their relation with cardiac remodeling during supplementation. We hypothesize that the Lactobacillus rhamnosus supplementation would attenuates the ventricular remodeling process after MI.

7. Methods/design

A two-arm parallel group randomized double-blind placebo controlled trial, was designed according to the CONSORT 2013 guidelines, and will be conducted over a period of one year from April 2018, in Tabriz, Iran. We will include 46 myocardial infarction patents who have been underwent successful percutaneous coronary intervention (PCI). The trial will be conducted at outpatient cardiology clinic of Shahid Madani Heart center affiliated to Tabriz University of Medical Sciences, Iran. All the patients will be screened by an expert cardiologist for eligibility which is presented in Table 1.

7.1. Allocation

Those who are willing to take part in the study will be carefully evaluated according to the inclusion criteria. Then, they will be requested to sign an informed consent and after that by using the Random Allocation Software, the subjects will be allocated into either probiotic or placebo group, stratified by sex, drugs intake and BMI. Participants and investigators will be blinded to the allocation of intervention (probiotic) or control (placebo) groups. Demographic information of the participants including age, height, weight, waist circumference, hip circumference will be collected. Primary and secondary outcomes measurement will be carried out at baseline and after intervention.
Table 1
Criteria for participation in the study.

| Inclusion criteria                                          | Exclusion criteria                                      |
|------------------------------------------------------------|---------------------------------------------------------|
| Patients who provide written informed consent              | Urgent need for revascularization procedure             |
| Both gender                                                 | Significant renal dysfunction (serum creatinine above 1.5 mg/dl) |
| Subjects ≥ 30 years of age                                  | Significant renal dysfunction (serum creatinine above 1.5 mg/dl) |
| First episode of MI after successful PCI                    | patients with severe liver and gastrointestinal diseases or diagnosis of diabetes mellitus |
| An echocardiographic LV EF ≥ 30%                            | allergy to studied agents; patients receiving immunosuppressive, anti-inflammatory and corticosteroid drugs; history of supplementation with pre/pro/symbiotic or antioxidants during or previous two months |
| BMI > 25 kg/m2                                               | Heart failure (function class III and IV), Heart valve diseases |
|                                                            | Refusal or inability to provide informed consent       |

7.2. Interventions

The participants will be randomized into two equal groups. The groups are probiotic (containing the freeze-dried 1.6 × 10^8 CFU Lactobacillus rhamnosus) or placebo (maltodextrin). The appearance and labeling of drug product of the two capsule are identical. The subjects will be educated to use Lactobacillus rhamnosus capsules or placebo capsules together with their lunch daily for 12 weeks.

7.3. Randomization

Individuals will be suitably blinded in performing outcome measurements and type of supplement. Letter A or B will be assigned to supplements and are otherwise identical. The person responsible for preparing the supplement capsule (who is completely unrelated to the study) will be asked to assign a three-digit code to each of the two capsules (probiotic and placebo), and keep the codes for himself until the end of the study and data analyses. The subjects in both groups will receive a weight loss diet considering their dietary habit. They will be recommended not to modify their physical activity habits. To ensure that these habits have not been changed during the study, the participants will be trained to record physical activity diaries, which will be checked weekly during visits by a specialist’s dietitian.

7.4. Follow-up

Study visits will be scheduled biweekly. During these visits, the researchers will check the compliance with dietary regime, supplements consumption and any side effects related to supplementation. Also, general questionnaire and a dietary recall questionnaire will be completed. A 24-h dietary recall questionnaire will be completed at the baseline, secondly middle of the intervention and also at the end of study.

The supervisor will assess and report adverse events of trial interventions. Compliance will be assessed based on returned tablet counts. Participant who miss > 10% of supplement dose at follow-up, will be excluded from the trial. Also, in the case of any changes in medication for example antibiotics consumption, or any other supplementation, the participants will be excluded from the study. An overview of study interventions and assessments is provided in Fig. 2.

7.5. Sample size

Calculation of sample size was based on a parallel two group randomized clinical trial with measurements of main outcomes at two time points. Considering the \( \alpha = 0.05 \) for type one error rate, and to provide 80% power for demonstrating the superiority of the study agents compared with placebo, 46 subjects were estimated [36].

7.6. Statistical analysis

Statistical analysis of all data will be performed using the SPSS program, version 16.0 (SPSS Inc., Chicago, IL) and P value < 0.05 will be considered statistically significant. To assess the efficacy of this trial, both per protocol approach and intention-to treat [37] principle [38], will be analyzed.

7.7. Outcome measurements

The changes of the biomarkers and echocardiographic indices of cardiac remodeling, which will be measured by laboratory assessments and 2-Dimensional Echocardiography is the primary outcome of this study. Two-dimensional echocardiography will be conducted at Shahid Madani Heart center affiliated to Tabriz University of Medical Sciences. Some echocardiographic indices including LVEDV and RVEDV will be calculated according to the biplane Simpson’s method.

7.8. Blood samples

After an overnight fasting, blood will be collected by the laboratory technician for measurement of biomarkers. The blood samples will be frozen at −80 °C until final processing. TGF. Beta, NT pro BNP, MMP-9, Procolagen I levels will be measured by specific ELISA kit. Measurement of total antioxidant capacity (TAC) and malondialdehyde (MDA) in serum will be done using Colorimetric Assay Kit. Lipid profile (TC, TG, LDL, HDL) and ox-LDL levels will be assessed by Pars Azmoon test kits (Pars Azmoon Inc, Tehran, Iran). Also serum levels of endotoxemia (TLR4 and LPS) and inflammatory stress indices (hs-CRP, IL1B, and IL-10) level will be measured using specific ELISA Kit.

7.9. Stool samples

The stool samples will be obtained at baseline and post intervention (after 3 months) in sterile plastic containers and will be delivered to the laboratory within 1 h of collection. Samples will be immediately frozen at −80 °C until assay. DNA will be extracted from fecal samples by DNA Extraction Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocols. Gut microbiota profile before and after probiotics supplementation will be determined by quantitative real-time polymerase chain reactions (RT-PCR) methodology via specific designed primers and Taqman probes.

7.10. Patient and public involvement

Patients and public were not involved in the design of this study, outcome measures, nor will they be involved with the conduct of the study. The recruitment plan was informed based on feedback from patients and public. A summary of the study results will be provided to each of the study participants. We will submit our findings for peer-review publication and presentation at national and international conferences.

7.11. Ethical issues & trial registration

Present study protocol was approved by the regional committee of ethics in international branch of Tabriz University of Medical sciences (TBZMED) as a thesis proposal for PhD degree in Nutrition Sciences (IR.TBZMED.REC.1397.184). Written informed consent will be taken
8. Discussion

The objective of this trial is to assess the effect of gut microbiota modulation on cardiometabolic risk factors and CR prevention after MI. The results of this study will provide evidence regarding the value of probiotic supplementation as an intervention for attenuating remodeling in patients with MI. As well as, we will evaluate the correlation between gut microbiota profile and CR processes in human subjects for the first time.

Despite the accepted roles of considerable pharmacotherapy such as ACE inhibitors in management of post-MI cardiac remodeling, the incidence rate is still noticeably high. Nevertheless, almost none of these therapeutic strategies cure the symptoms, and all of them cause great economic burdens to the patient and healthcare system (3, 4). Although the pattern of post-MI remodeling may exhibit a different picture, clinical guidelines recommend different methods to reduce the risk of cardiac remodeling in clinical trials. In CR process, during MI cell death and fibroblast recruitment take place resulting in collagen accumulation and cardiac fibrosis which lead to HF [39,40]. According to CR processes, fibrosis and inflammation are key pathological phenomenon of HF [41] and this study may show that a probiotic administration could attenuate this progression.

Disruption of gut microbiota profile has been implicated in many conditions and diseases such as diabetes and CVD. Previous evidence suggests that inhibition or treating these conditions might be achieved by manipulation of the gut microbiota [3]. Probiotic administration has been considered as an effective and safe approach for the treatment of various diseases such as cardiometabolic diseases [33]. Based on previous study, probiotics have shown effects on CVD through variety of mechanisms including production of organic acids, diminishing endotoxemia, inducing immune mediators, and by anti-inflammatory effect [33]. Evidence suggests that endotoxemia resulting from dysbiosis is a possible trigger of systemic inflammation which probably plays an important role in the pathogenesis and progression of HF [42]. In fact, LPS has been shown to exert proinflammatory effect which accelerates HF development [43]. Moreover, gut modulation with antibiotics or pre/probiotics improved gut permeability, reduced endotoxia, lowered inflammation and increased quality of life in patients with HF [44]. In addition, it seems that gut modulation could attenuate CR process which might progress to HF [3,45]. With regard to HF, numerous studies have revealed that probiotics exert hypertrophic effects under ischemic conditions. Furthermore, clinical studies have shown that probiotic administration can potentially be helpful in prevention of cardiac failure and improvement of quality of life [3,46]. Our study maybe will be show a CR process, which was prevented by probiotics. On the other hand, the other important outcome of gut modulation with probiotics is that it can enable sensibly controlled metabolic endotoxemia and subsequent outcomes [47].

Recently, TMAO has been identified as a novel risk factor for the development of HF. It has been shown TMAO significantly elevated in CAD patients with HF compared to control subjects [28]. As well as, TMAO levels were strongly linked with gut microbiota profile and recently it has been shown that, gut modulation was associated with decrease in TMAO levels [17]. Based on recent findings, it is proposed that probiotics have beneficial effects on remodeling process. One notable mechanism of probiotics is its capability in attenuation of harmful gut metabolite such as TMAO which accelerate ventricular dysfunction. However, it has been proposed that TMAO levels were not associated

![Image](http://en.irct.ir/user/trial/30121/view)
with plasma LPS levels, suggesting that additional duplication effect of probiotics in HF prevention. These outcomes develop a hypothesis that guts modulation with probiotics supplementation might serve as an alternative method to treat CR process [17,26,27].

In addition, Lactobacillus rhamnosus as probiotics demonstrates significant benefits by anti-proliferative and anti-apoptotic effect in cardiomyocytes derived following myocardial infarction and attenuates myocardial hypertrophy and heart failure. More recently, Chao-Hung Lai et al. [48] showed that supplementation with multi-strain probiotics may attenuate cardiomyocyte fibrosis, cardiac hypertrophy and the autophagy-signaling pathway in high-fat diet-fed rats. In addition, previous studies showed that oral administration of probiotics promoted cardiac survival through activation of the PI3K/Akt pathway and decreased inflammatory markers and expression of fibrosis protein in hypertensive rats [49]. Indeed, probiotics supplementation may attenuate CR process through suppression of TLR-4-related inflammatory pathway and may have an anti-fibrosis effect [50].

However, the limitations of this study should also be considered. First, short duration of the intervention, as participants will be treated for only 12 weeks, whereas CR process development might progress in the longer period. Additionally, our sample size was relatively small. However, this study has a strong point which is the controlling main dietary substrates for TMAO formation. Secondly, we will measure the gut microbiome and gut metabolite together at the same time to firmly establish the gut microbiota as a risk factor for CR.

In conclusion, as far as we are aware, there is a lack of evidence regarding the management of post-MI cardiac remodeling. To the best of our knowledge, this is the first study which has been designed to assess the effects of probiotic supplementation in post-MI patients by measuring the major biomarkers and echocardiographic indices. The underlying mechanisms for these effects have not been understood yet; however, initial evidence suggests the amelioration of metabolic endotoxemia and decrease of low-grade inflammation and TMAO levels could attenuate these processes. Although our study has a relatively small sample size, this trial may play a vital role in providing basic clinical data in management of post-MI cardiac remodeling. In this trial using oral administration of probiotics, offers a new approach for post-MI cardiac remodeling. We also anticipate that probiotics supplementation will improve metabolic endotoxemia, lipid pro- liferation, and inflammatory status by altering the gut microbiota composition. If the results of the investigation show are effective, it will serve as a new strategy for CHF prevention. We hope this RCT will provide scientific evidence in supporting probiotics intervention for attenuating CR in MI patients.

Author contributions

Conceived and designed the experiments: JM MA. Performed the experiments: JM AG. Analyzed the data: JM VM MD. Wrote the paper: All of authors.

Conflicts of interest

The authors declare that they have no conflict of interest.

9. Trial status

The study was conceived and designed in 2018. The recruitment of the trial is ongoing.

Acknowledgements

We would like to thank all members of present study group for their ideas, suggestions, participation and support. As well as, the authors wish to thank Tabriz University of Medical Science for financial support.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ACE | Angiotensin-converting enzyme |
| MI | Myocardial infarction |
| LV | Left ventricle |
| EF | Ejection fraction |
| ELISA | enzyme-linked immunosorbent assay |
| hs-CRP | high-sensitive C-Reactive protein |
| HF | heart failure |

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.conctc.2019.100364.

Funding/support

The study was supported financially by Tabriz University of Medical Science as a thesis proposal for Ph.D. degree of the first author.

References

[1] D. Lloyd-Jones, R. Adams, M. Carnethon, G. De Simone, T.B. Fergusson, K. Flegel, et al., Heart disease and stroke statistics—2009 update: a report from the American heart association statistics committee and stroke statistics committee, Circulation 119 (3) (2009) e21-e181.
[2] V.L. Roger, Epidemiology of heart failure, Circ. Res. 113 (6) (2013) 646–659.
[3] X.T. Gu, G. Ettinger, C.X. Huang, J.P. Burton, J.V. Haist, V. Rajapakshatil, et al., Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the RatCLINICAL PERSPECTIVE, Circulation: Heart Fail. 7 (3) (2014) 491–499.
[4] W.C. Levy, D. Mozaffarian, D.T. Linker, S.C. Santurkar, S.D. Anker, A.B. Cropp, et al., The Seattle Heart Failure Model: prediction of survival in heart failure, Circulation 113 (11) (2006) 1424–1433.
[5] A. Sadeghpour, H. Pouraliakbar, R. Azarfarin, A.A. Ghavidel, S. Zavareian, A. Amirahmadi, Mid-term patency in radial artery and saphenous vein after coronary artery bypass grafting in asymptomatic patients using 128-slice CT coronary angiography, Anesthesiology and pain medicine 5 (1) (2015).
[6] S.M. Grundy, L.J. Benjamin, G.L. Burke, A. Chait, R.H. Eckel, B.V. Howard, et al., Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association, Circulation 100 (10) (1999) 1134–1146.
[7] J.N. Cohn, R. Ferrari, N. Sharpe, Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling, J. Am. Coll. Cardiol. 35 (3) (2000) 569–582.
[8] K. Dracup, J. Walden, L. Stevenson, M. Brecht, Quality of life in patients with advanced heart failure, J. Heart Lung Transplant.: the official publication of the International Society for Heart Transplantation 11 (2 Pt 1) (1992) 273–279.
[9] M.S. Nieminen, K. Dickstein, F. Fonseca, J.M. Serrano, J. Parissis, F. Fedele, et al., The patient perspective: quality of life in advanced heart failure with frequent hospitalisations, Int. J. Cardiol. 191 (2015) 256–264.
[10] M.G.S-J. Sutton, N. Sharpe, Left ventricular remodeling after myocardial infarction: pathophysiology and therapy, Circulation 101 (25) (2000) 2981–2988.
[11] R.G. Mickay, M.A. Pfeffer, R.C. Pasternak, J.E. Markis, P.C. Come, S. Nakao, et al., Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion, Circulation 74 (4) (1986) 693–702.
[12] M. Nian, P. Lee, N. Khaper, P. Liu, Inflammatory cytokines and postmyocardial infarction remodeling, Circ. Res. 94 (12) (2004) 1543–1553.
[13] D. Fraccarollo, P. Galuppo, S. Hildemann, M. Christ, G. Ertl, J. Bauersachs, Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction, J. Am. Coll. Cardiol. 42 (9) (2003) 1666–1673.
[14] G.V. Halade, Y.-F. Jin, M.L. Lindsey, Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation, Pharmacol. Ther. 139 (1) (2013) 32–40.
[15] G. Masoumi, E. Hidarpoor, A.S. Tabae, M. Ziaieefard, A. Azarara, A. Abneshahidi, S.J. Anbardan, P. Kashefian, D.T. Linker, S.C. Sutradhar, S.D. Anker, et al., Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis, J. Am. Coll. Cardiol. 64 (18) (2014) 1908–1914.
[16] W.W. Tang, S.L. Hazen, The contributory role of gut microbiota in cardiovascular disease, J. Clin. Investig. 124 (10) (2014) 4204–4211.
[19] C.W. McIntyre, L.E. Harrison, M.T. Eldhaini, H.J. Jefferies, C.-C. Szeto, S.G. John, et al., Circulating endotoxins: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease, Clin. J. Am. Soc. Nephrol. 6 (1) (2011) 133–141.

[20] P.D. Cani, R. Bibiloni, C. Knaufl, A. Waget, A.M. Neryrinn, N.M. Delzenne, et al., Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice, Diabetes 57 (6) (2008) 1470–1481.

[21] J.C. Chow, D.W. Young, D.T. Golenbock, W.J. Christ, F. Gusovsky, Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction, J. Biol. Chem. 274 (16) (1999) 10689–10692.

[22] M. Triantafiou, K. Triantafiou, Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster, Trends Immunol. 23 (6) (2002) 301–304.

[23] H. Stapel, S.C. Kim, S. Osterkamp, P. Knuefermann, A. Hoeft, R. Meyer, et al., Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways, Infect. Immun. 74 (7) (2006) 4075–4082.

[24] W. Feleszko, J. Jaworska, E. Hamelmann, Toll-like receptors—novel targets in allergic airway disease (probiotics, friends and relatives), Eur. J. Pharmacol. 533 (1–3) (2006) 308–318.

[25] W.W. Tang, S.L. Hazen, Reply: trimethylamine-N-oxide and heart failure, J. Am. Coll. Cardiol. 61 (1) (2013) 96–97.

[26] M. Trøseid, T. Ueland, J. Hov, A. Svardal, I. Gregersen, C. Dahl, et al., Toll-like receptors: a systematic review and meta-analysis of randomized controlled trials, Ann. Intern. Med. 160 (7) (2014) 459–470.

[27] M.M. Seldin, Y. Meng, H. Qi, W. Zhu, Z. Wang, S.L. Hazen, et al., Trimethylamine N-oxide generates an inflammatory pathway and anti-inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial, Mediat. Inflamm. 2014 (2014).

[28] T.R. Ten Have, S.L.T. Normand, S.M. Marcus, C.H. Brown, P. Lavori, N. Duan, Intent-to-treat vs. non-intent-to-treat analyses under treatment non-adherence in mental health randomized trials, Psychiatr. Ann. 38 (12) (2008).

[29] J.J. Gajarsa, R.A. Kloner, Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities, Heart Fail. Rev. 16 (1) (2011) 13–21.

[30] P.W. Fedak, S. Verma, R.-K. Li, Cardiac remodeling and failure: from molecules to man (Part I), Cardiovasc. Pathol. 14 (1) (2005) 1–11.

[31] A. Nicoletti, J.-B. Michel, Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors, Cardiovasc. Res. 41 (3) (1999) 532–543.

[32] G. Escobedo, E. Lopez-Ortiz, I. Torres-Castro, Gut microbiota as a key player in triggering obesity, systemic inflammation and insulin resistance, Rev. Invest. Clin. 66 (5) (2014) 450–459.

[33] J. Danesh, J.G. Wheeler, G.M. Hirschfield, S. Eda, G. Eiriksdottir, A. Rumley, et al., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N. Engl. J. Med. 350 (14) (2004) 1387–1397.

[34] P. Dehghan, B.P. Gargari, M.A. Jalal-Abadi, A. Aliashgarzadeh, Inulin controls inflammation and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized-controlled clinical trial, Int. J. Food Sci. Nutr. 65 (1) (2014) 117–123.

[35] E. Pasini, R. Aquilani, C. Testa, P. Biaardi, S. Angioletti, F. Boschi, et al., Pathogenic gut flora in patients with chronic heart failure, JACC (J. Am. Coll. Cardiol.): Heart Fail. 4 (3) (2016) 220–227.

[36] Y. Nagatomo, W.W. Tang, Intersections between microbiome and heart failure: revisiting the gut hypothesis, J. Card. Fail. 21 (12) (2015) 973–980.

[37] A.C. Costanza, S.D. Moscovich, H.C.F. Neto, E.T. Mesquita, Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial, Int. J. Cardiol. 179 (2015) 348–350.

[38] C.-H. Lai, C.-C. Tsai, W.-W. Kuo, T.-J. Ho, C.-H. Day, P-y Pai, et al., Multi-strain probiotics inhibit cardiac myopathies and autophagy to prevent heart injury in high-fat diet-fed rats, Int. J. Med. Sci. 13 (4) (2016) 283–287.

[39] P.-P. Lin, Y.-M. Hsieh, W.-W. Kuo, Y.-M. Lin, Y.-L. Yeh, C.-C. Lin, et al., Suppression of TLR-4-related inflammatory pathway and anti-fibrosis effects of probiotic-fermented purple sweet potato yogurt activates compensatory IGBP-IR/PEAK/Akt survival pathways and attenuates cardiac apoptosis in the hearts of spontaneously hypertensive rats, Int. J. Mol. Med. 32 (6) (2013) 1319–1328.